Amendment to Employment Agreements between ARIAD Pharmaceuticals, Inc. and Executive Officers
Contract Categories:
Human Resources
›
Employment Agreements
Summary
ARIAD Pharmaceuticals, Inc. amended its employment agreements with several executive officers on October 14, 2008, extending their employment terms by one to three years, depending on the individual. The agreement covers positions such as CEO, CFO, and other senior executives. After the new term ends, each agreement will automatically renew for additional one-year terms (three years for the CEO) unless either the company or the executive provides notice to end the agreement.
EX-10.23 7 a5915319-ex1023.htm EXHIBIT 10.23 a5915319-ex1023.htm
Exhibit 10.23
AMENDMENTS TO EMPLOYMENT AGREEMENTS
ARIAD Pharmaceuticals, Inc. (the “Company”) entered into an amendment to the employment agreement between the Company and each of the following executive officers, on October 14, 2008, to extend the term of employment thereunder as follows:
| Term of Agreement Extended | ||
| Name and Title | From | To |
| (December 31 of each year) | ||
| Harvey J. Berger, M.D. Chairman and Chief Executive Officer | 2011 | 2013 |
| David L. Berstein, Esq. Senior Vice President, Chief Intellectual Property Officer | 2010 | 2011 |
| Timothy P. Clackson, Ph.D. Senior Vice President, Chief Scientific Officer | 2010 | 2012 |
| Edward M. Fitzgerald Senior Vice President, Chief Financial Officer and Treasurer | 2010 | 2012 |
| Pierre F. Dodion, M.D. Senior Vice President, Chief Medical Officer | 2009 | 2011 |
| Raymond T. Keane, Esq. Vice President, General Counsel, Secretary and Chief Compliance Officer | 2010 | 2011 |
| Matthew E. Ros Vice President, Commercial Operations | 2010 | 2011 |
The term of employment for each officer is thereafter subject to automatic renewal for successive one-year terms (three-year terms in the case of Dr. Berger) absent notice to the contrary by either party.
